Navigation Links
Elagolix Successful in Six Month Lilac Petal Study; Safety and Efficacy Confirmed in Patients With Endometriosis
Date:7/29/2009

SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new six month safety and efficacy results from its fourth Phase II clinical trial using its proprietary, orally-active non-peptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis. Consistent with previously reported six month (Petal Study) and three month (Lilac Petal Study) results, a favorable safety profile and clinically meaningful efficacy have again been confirmed through month six of the Lilac Petal Study. This newly available data also provides clinical confirmation of Neurocrine's extensive pharmacologic modeling related to the elagolix dose-response continuum. The outcome of primary interest at month six was the impact of the elagolix 250 mg dose on bone mineral density (BMD) as measured by dual energy X-ray absorptiometry (DXA) scanning.

Over the six month treatment period, elagolix 150 mg once daily had minimal impact on BMD (-0.80% mean change from baseline, femur; -0.66% mean change from baseline, spine). The 250 mg once daily dose, as expected, had slightly greater percentage change from baseline at month six (-1.0% femur, -1.6% spine). The 150 mg once daily BMD profile in this Lilac Petal Study is consistent with that previously demonstrated in the six-month Petal Study.

"We selected the 150 mg and 250 mg once daily doses for this study based upon predictions generated from extensive modeling of dose, estradiol and bone mineral density relationships. Prior to this study we anticipated that the 250 mg dose would provide exposure such that we would start to see an increased impact on bone mineral density in a small portion of study subjects. The Lilac Petal data confirm that our modeling of the dose-response curve was accurate," said C
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech Inc. Successfully Completes 100-Litre cGMP Production of REOLYSIN(R)
2. Blue Marble Energy Corp. Announces Successful Close of Series A Financing
3. EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP-6124 Phase Ib/IIa Trial at the International Conference on Alzheimers Disease
4. Funxional Successfully Completes Initial Clinical Trial of FX125L, an Anti-Inflammatory Drug With a Novel Mechanism of Action
5. Enigma Diagnostics Announces Successful Evaluation of the Enigma FL by the UKs Veterinary Laboratories Agency
6. PharmaVentures Assists Helsinn in the Successful Sale of Helsinn Chemicals Ireland to the Medinco C.F.M. Group
7. Successful Field-Trial Remediation of 1,2-DCA and VC Contaminated Groundwater in Northern Italy
8. Orthocrat Announces Successful Implementation of TraumaCad at UPMC Mercy
9. Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB
10. Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy
11. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Biotech Inc. (TSX:,ONC, NASDAQ: ONCY) announced today ... a poster presentation entitled "In Vivo Efficacy ... in,Nude Mice Bearing Human Melanoma Xenografts" at ... Cancer Therapeutics. SAIC-Frederick is,the prime contractor to ...
... Biosystems,Inc. (OTC Bulletin Board: WGBS), a leading developer ... cell research systems,today announced that Alnoor Shivji, WaferGen,s ... presentation at the Seventh,Annual BIO Investor Forum. The ... Palace Hotel in San Francisco, WaferGen,s presentation ...
... Soliris(R) in U.S. and Europe, Reported Net Sales ... Quarter Shipments, Company Revises Revenue Guidance Upward and ... 2008, Pipeline Progress in Hematology, Oncology, Transplant, Neurology, ... (eculizumab) net product sales of $76.5 million in Q3,2008 ...
Cached Biology Technology:Oncolytics Biotech Inc. Collaborators Present Reovirus and Melanoma Research at EORTC-NCI-AACR Symposium 2Oncolytics Biotech Inc. Collaborators Present Reovirus and Melanoma Research at EORTC-NCI-AACR Symposium 3WaferGen to Present at the Seventh Annual BIO Investor Forum 2Alexion Reports Third Quarter 2008 Results 2Alexion Reports Third Quarter 2008 Results 3Alexion Reports Third Quarter 2008 Results 4Alexion Reports Third Quarter 2008 Results 5Alexion Reports Third Quarter 2008 Results 6Alexion Reports Third Quarter 2008 Results 7Alexion Reports Third Quarter 2008 Results 8Alexion Reports Third Quarter 2008 Results 9Alexion Reports Third Quarter 2008 Results 10Alexion Reports Third Quarter 2008 Results 11Alexion Reports Third Quarter 2008 Results 12Alexion Reports Third Quarter 2008 Results 13Alexion Reports Third Quarter 2008 Results 14
(Date:11/21/2014)... Nov. 20, 2014 C-Labs LLC, a leading ... of Things (IoT), today announced the appointment of ... officer. Previously a strategic advisor to the firm, Mr. ... Mr. Traynor is based out of the C-Labs office ... to Chris Muench , Chief Executive Officer. ...
(Date:11/18/2014)... 2014 The Parenteral Drug Association (PDA) today confirmed ... speak and at least seven more will participate in the ... Shoreham Hotel in Washington D.C. , Dec. ... significant support from the regulatory agencies in the ... in our effort to help advance the use of metrics ...
(Date:11/11/2014)... 11, 2014  Forensicon, Inc., a Chicago ... to announce the promotion of Yaniv Schiff ... Forensics. In Schiff,s new role as Director, he will ... digital forensics examiners and provide leadership within the company,s ... http://photos.prnewswire.com/prnh/20141110/157719 Schiff joined Forensicon ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2
... HERNDON, Va., Aug. 5, 2011 GTSI Corp. (NASDAQ: ... integrator for federal, state and local governments, announced today ... by the U.S. Army.  This contract will provide war ... of persons of interest in the field. The contract ...
... PARK, Md. -- New computer modeling work shows that by ... atmosphere to less than 40 percent higher than it is ... means of reducing emissions. This includes more nuclear and renewable ... that capture and store carbon dioxide, and even using forests ...
... dinosaurs that lived near the South Pole, sometimes in the ... similar to dinosaurs that lived everywhere on the planet, according ... surprising fact falsifies a 13-year-old study and may help explain ... million years, said Holly Woodward, MSU graduate student in the ...
Cached Biology News:GTSI Wins Department of Defense Contract to Provide Biometric Automated Toolset Systems for U.S. Army 2Human influence on the 21st century climate: 1 possible future for the atmosphere 2Human influence on the 21st century climate: 1 possible future for the atmosphere 3Human influence on the 21st century climate: 1 possible future for the atmosphere 4New Montana State research sheds light on South Pole dinosaurs 2New Montana State research sheds light on South Pole dinosaurs 3
KNP-1 (HES1) Purified Anti-Mouse, Anti-Rat, Anti-Human, Anti-Dog, Anti-Chicken clone 35, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
NATIVE RAT OSTEOCALCIN...
Form: Ready to use Applications: ELISA...
Goat polyclonal to p27 KIP 1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: C-KRPATDDS STQNK, corresponding to Internal sequence amino acids 153-165 of Human p27 KIP 1 ...
Biology Products: